PubMed RSS Feed - -Acneiform eruptions caused by various second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.

[rss]

Related Articles

Acneiform eruptions caused by various second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.

Br J Dermatol. 2015 Sep 24;

Authors: Jung YS, Kim M, Lee JH, Cho BK, Kim DW, Park HJ

Abstract
Tyrosine kinase inhibitors (TKIs) are a novel, well-tolerated and promising class of anticancer drugs, commonly used to treat chronic myeloid leukaemia (CML). Imatinib was the first commercially available TKI, approved for the treatment of CML and gastrointestinal stromal tumours. The development of polyclonal resistances to imatinib, due to point mutations in the bcr-abl kinase domain, yielded second generation TKIs including dasatinib, radotinib, and nilotinib. (1) These second generation TKIs have shown higher rates of early optimal responses and fewer side effects when compared to imatinib. (1) These new agents are indeed less toxic, but the range of activity of these drugs is still not only directed at tumour cells. As a result, their use is associated with various systemic adverse events that go beyond the scope of the present review, but cutaneous side effects are the most commonly reported. (1,2) Nevertheless, there have only been few reports of cutaneous adverse events caused by TKIs in CML patients. To the best of our knowledge, this is the first report directly focused on acneiform eruptions due to second generation TKIs in CML patients. Herein, we report 10 cases of acneiform eruptions with or without rosacea-like eruptions caused by various second generation TKIs in CML patients. This article is protected by copyright. All rights reserved.

PMID: 26399382 [PubMed - as supplied by publisher]

{url} = URL to article